IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

E. R. Froesch, T. Bianda, Mehboob Hussain

Research output: Contribution to journalArticle

Abstract

Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

Original languageEnglish (US)
Pages (from-to)261-267
Number of pages7
JournalDiabetes and Metabolism
Volume22
Issue number4
Publication statusPublished - Jul 1996
Externally publishedYes

    Fingerprint

Keywords

  • growth hormone
  • insulin resistance
  • insulin sensitivity
  • insulin-like growth factor-I
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this